A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.

Jingquan Jia,Donna Niedzwiecki,Hope E. Uronis,Michael A. Morse,Yousuf Zafar,Shiaowen David Hsu,Emily Bolch,Rebecca J. Nagy,Richard B. Lanman,AmirAli Talasaz,Sherri Haley,Andrew B. Nixon,John H. Strickler

A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.

2018

Jingquan Jia
Donna Niedzwiecki
Hope E. Uronis
Michael A. Morse
Yousuf Zafar
Shiaowen David Hsu
Emily Bolch
Rebecca J. Nagy
Richard B. Lanman
AmirAli Talasaz
Sherri Haley
Andrew B. Nixon
John H. Strickler

3555Background: MET amp is a well described driver of acquired EGFR antibody (Ab) resistance. Blood-based genomic profiling of cell free (cf)DNA is a safe and efficient means to identify pts with a...

Keywords:

Wild type
Pathology
Panitumumab
Cancer research
Colorectal cancer
Medicine
Cabozantinib
met amplification
EGFR Antibody
in patient
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations